[attention] in January 2019, two Asian forums will be held, and these 18 meetings will be waiting for you

In January 2019, the exhibition is quiet and the forum has not stopped "Asia Pacific pharmaceutical Summit Forum (appsf)" and "2019 Asia Pharmaceutical R & D leaders summit" will be held soon There are also hot and timely meetings in China, "4 + 7 high end dialogue seminar of pharmaceutical industry in the context of volume procurement", but compared with other months, they are relatively cold However, many organizers have prepared in advance and issued the 2019 conference notice, most of which are Shanghai exhibitions and conferences Let's take a look at the recommendation index of the 2019 Asia Pharmaceutical R & D Summit On January 21-22, 2019, the 2019 (9th) Asia Pharmaceutical R & D leaders summit will be held in Beijing, which is sponsored by SRM and jointly supported by Sapa, CBA and tbio With the theme of "looking at Asia from here, to meet the clinical needs of the world", this conference discusses the current global R & D trends, R & D strategies, innovation capacity building and cooperation opportunities and other hot topics Top executives of zaiding pharmaceutical, Fuhong Hanlin, Tianjing biology, Lizhu pharmaceutical and other international companies will attend the meeting, as well as Asia Pacific leaders of bringer Ingelheim, Johnson & Johnson, Lilly, Pfizer and other international companies will present their own suggestions A number of cro companies, including Shanghai Lidi biotechnology, Midu (Nanjing) biotechnology, TIMA biomedical technology and Hangzhou tag Pharmaceutical Co., Ltd., sponsored the conference and will arrange exhibitions at the conference Appsf Recommendation Index: ★★★ on January 9-10, 2019, the "appsf" sponsored by Shanghai Shengjie Enterprise Management Consulting Co., Ltd and IPA will be held in Shanghai At present, there are 119 pharmaceutical companies approved by FDA in India These companies can export about 900 FDA approved drugs and raw materials to the United States How can the Chinese market learn from the "Indian experience"? It is expected that there will be ten patents of biological drugs with leading market share expire between 2015 and 2020, which will bring huge profit space of up to 70 billion dollars to other pharmaceutical companies How can we seize the opportunity? Although China has become the second largest pharmaceutical market in the world, the proportion of innovative drugs with independent intellectual property rights is very low, only 18%, far below the level of the United States, Europe and Japan How to break through innovation? In response to the above issues, the sponsor invited a number of Indian experts such as chairman of the Indian Pharmaceutical Committee, chairman of the Indian Pharmaceutical Association, Professor of the Pharmaceutical Research Institute of pangab University and other Indian experts to attend and guide the maze, and discussed topics such as the R & D roadmap of new drugs in China, the strategic prospect of the generic pharmaceutical industry, the concept and application of QBD, and the analysis and application of biological similar drugs Recommended index of high-end dialogue seminar of pharmaceutical industry in the context of 4 + 7 volume procurement On January 11-12, 2019, the "development planning, marketing strategy, R & D pipeline -- high end dialogue seminar of pharmaceutical industry in the context of 4 + 7 volume procurement" held by Beijing Peiyou innovative pharmaceutical biotechnology will be held in Beijing The seminar will interpret the "4 + 7 volume procurement" policy, analyze and evaluate the impact of the volume procurement policy on the industry, and analyze "4 + 7" based on big data The idea and strategy of drug R & D project under the mode of "etc Bi Kaishun, professor and doctoral supervisor of Shenyang Pharmaceutical University, Dr Zhang Ran, vice president of China Chemical Pharmaceutical Industry Association and director of the special committee of policies and regulations and director of the special committee of listed companies, and sun Liying, former FDA review leader, medical doctor and doctoral director, will attend the guidance In addition to the wonderful meetings in January, exhibitions and conference previews in February 2019 and beyond have also been published, including the 9th International Summit on generic drugs (Asia), the 19th World pharmaceutical raw materials China Exhibition and the 14th world pharmaceutical machinery, packaging equipment and materials China exhibition, etc.: the notice of the 2019 wonderful conference and the notice of the 2019 wonderful exhibition The above conference content and Exhibition notice content are all from the conference column of news.yaozh.com This column is free for people in the pharmaceutical industry In 2019, friends who have wonderful activities to be exposed can register their members for free, and then publish them with one click (free website: https://news.yaozh.com/meeting/apply.html, click to enter) Statement: this opinion only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.